Groundbreaking Application of Gene Editing Tool on Plants Provides New Tool for Opioid Management
Dublin, California, October 5, 2022 – Emerzene Inc (www.emerzenetx.com), an Agri biotech start-up based in Dublin, California, USA, today announced it has licensed a non-exclusive research use patented CRISPR-Cas9 gene editing technology through an agreement with Sigma Aldrich Co. LLC, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany. This research licensing agreement paves the way for Emerzene researchers and scientists to enhance plant genome ed
